<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clinical Workflow - Pipeline Documentation</title>
    <script src="https://cdn.jsdelivr.net/npm/mermaid/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({ 
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                useMaxWidth: true,
                htmlLabels: true
            }
        });
    </script>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            line-height: 1.6;
            color: #333;
            background: #f5f7fa;
        }
        
        .header {
            background: linear-gradient(135deg, #f06292 0%, #ba68c8 100%);
            color: white;
            padding: 2rem;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
        }
        
        .header h1 { font-size: 2rem; margin-bottom: 0.5rem; }
        .back-link { color: white; text-decoration: none; opacity: 0.9; display: inline-block; margin-bottom: 1rem; }
        .back-link:hover { opacity: 1; }
        
        .container { max-width: 1400px; margin: 0 auto; padding: 2rem; }
        
        .section {
            background: white;
            border-radius: 12px;
            padding: 2rem;
            margin-bottom: 2rem;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
        }
        
        .section h2 {
            color: #f06292;
            margin-bottom: 1.5rem;
            padding-bottom: 0.5rem;
            border-bottom: 3px solid #f06292;
        }
        
        .section h3 {
            color: #ba68c8;
            margin: 1.5rem 0 1rem 0;
        }
        
        .mermaid {
            background: white;
            padding: 1rem;
            border-radius: 8px;
            margin: 1rem 0;
        }
        
        .critical-box {
            background: #ffebee;
            border-left: 4px solid #f44336;
            padding: 1rem;
            margin: 1rem 0;
            border-radius: 4px;
        }
        
        .critical-box strong {
            color: #f44336;
            display: block;
            margin-bottom: 0.5rem;
        }
        
        .high-priority-box {
            background: #fff3e0;
            border-left: 4px solid #ff9800;
            padding: 1rem;
            margin: 1rem 0;
            border-radius: 4px;
        }
        
        .high-priority-box strong {
            color: #ff9800;
            display: block;
            margin-bottom: 0.5rem;
        }
        
        .treatment-box {
            background: #e8f5e9;
            border-left: 4px solid #4caf50;
            padding: 1rem;
            margin: 1rem 0;
            border-radius: 4px;
        }
        
        .treatment-box strong {
            color: #4caf50;
            display: block;
            margin-bottom: 0.5rem;
        }
        
        .data-table {
            width: 100%;
            border-collapse: collapse;
            margin: 1.5rem 0;
        }
        
        .data-table th {
            background: #f06292;
            color: white;
            padding: 0.75rem;
            text-align: left;
            border: 1px solid #ddd;
        }
        
        .data-table td {
            padding: 0.75rem;
            border: 1px solid #ddd;
        }
        
        .data-table tr:nth-child(even) {
            background: #f8f9fa;
        }
        
        code {
            background: #f4f4f4;
            padding: 0.2rem 0.4rem;
            border-radius: 3px;
            font-family: 'Courier New', monospace;
            font-size: 0.9em;
        }
        
        .module-card {
            background: #f8f9fa;
            border-radius: 8px;
            padding: 1.5rem;
            margin-bottom: 1.5rem;
            border-left: 4px solid #f06292;
        }
        
        .module-card h4 {
            color: #ba68c8;
            margin-bottom: 1rem;
        }
        
        .note-box {
            background: #e8eaf6;
            border-left: 4px solid #3f51b5;
            padding: 1rem;
            margin: 1rem 0;
            border-radius: 4px;
        }
        
        .note-box strong {
            color: #3f51b5;
        }
        
        .priority-badge {
            display: inline-block;
            padding: 0.3rem 0.8rem;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
            margin-right: 0.5rem;
        }
        
        .critical { background: #f44336; color: white; }
        .high { background: #ff9800; color: white; }
        .medium { background: #ffc107; color: #333; }
        .low { background: #4caf50; color: white; }
    </style>
</head>
<body>
    <div class="header">
        <div class="container">
            <a href="index.html" class="back-link">‚Üê Back to Overview</a>
            <h1>üíä Clinical Workflow Documentation</h1>
            <p>Evidence-based clinical interpretation and treatment recommendations for AMR profiling</p>
        </div>
    </div>
    
    <div class="container">
        <!-- Overview -->
        <div class="section">
            <h2>Clinical Workflow Overview</h2>
            <p><strong>Status:</strong> Currently commented out in pipeline but fully designed and ready for implementation</p>
            <p><strong>Purpose:</strong> Transform AMR detection data into actionable clinical decisions with evidence-based treatment recommendations</p>
            
            <h3>Workflow Integration</h3>
            <p>The Clinical Workflow receives outputs from the AMR Profiler Workflow:</p>
            
            <div class="mermaid">
graph LR
    AMR[AMR Profiler<br/>Workflow] --> Chrom[Chromosomal<br/>Mutations]
    AMR --> HGT[HGT Gene<br/>Presence]
    AMR --> Alleles[penA/porB/mtrR<br/>Alleles]
    AMR --> NGStar[NG-STAR<br/>Typing]
    
    Chrom --> Clinical[Clinical<br/>Workflow]
    HGT --> Clinical
    Alleles --> Clinical
    NGStar --> Clinical
    
    Clinical --> Treatment[Treatment<br/>Recommendations]
    Clinical --> Priority[Priority<br/>Alerts]
    Clinical --> Report[Clinical<br/>Reports]
    
    style AMR fill:#ab47bc,stroke:#7b1fa2,stroke-width:2px,color:#fff
    style Clinical fill:#f06292,stroke:#c2185b,stroke-width:3px,color:#fff
    style Treatment fill:#4caf50,stroke:#388e3c,stroke-width:2px,color:#fff
    style Priority fill:#ff9800,stroke:#f57c00,stroke-width:2px,color:#fff
    style Report fill:#2196f3,stroke:#1976d2,stroke-width:2px,color:#fff
            </div>
            
            <h3>Four-Step Process</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Step</th>
                        <th>Module</th>
                        <th>Input</th>
                        <th>Output</th>
                        <th>Purpose</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>1</strong></td>
                        <td>APPLY_CLINICAL_RULES</td>
                        <td>All AMR data</td>
                        <td>Annotated data + alerts</td>
                        <td>Match detected markers to clinical rules database</td>
                    </tr>
                    <tr>
                        <td><strong>2</strong></td>
                        <td>PRIORITY_CLASSIFICATION</td>
                        <td>Annotated data</td>
                        <td>Priority levels</td>
                        <td>Classify samples by clinical urgency</td>
                    </tr>
                    <tr>
                        <td><strong>3</strong></td>
                        <td>TREATMENT_RECOMMENDATION</td>
                        <td>Prioritized data</td>
                        <td>Treatment plans</td>
                        <td>Generate evidence-based treatment options</td>
                    </tr>
                    <tr>
                        <td><strong>4</strong></td>
                        <td>GENERATE_CLINICAL_REPORT</td>
                        <td>All AMR data</td>
                        <td>HTML report</td>
                        <td>Create comprehensive clinical report</td>
                    </tr>
                </tbody>
            </table>
        </div>
        
        <!-- Detailed Workflow -->
        <div class="section">
            <h2>Detailed Workflow Steps</h2>
            
            <div class="mermaid">
graph TB
    Start[AMR Data Input] --> Merge[Merge All AMR Outputs]
    
    Merge --> Rules[Step 1:<br/>APPLY_CLINICAL_RULES<br/>Match to Clinical Rules Database]
    
    Rules --> Annotated[Annotated AMR Data]
    Rules --> Alerts1[Clinical Alerts]
    
    Annotated --> Priority[Step 2:<br/>PRIORITY_CLASSIFICATION<br/>Assign Clinical Priority]
    Alerts1 --> Priority
    
    Priority --> Prioritized[Prioritized Data]
    Priority --> Alerts2[Priority Alerts]
    
    Prioritized --> Treatment[Step 3:<br/>TREATMENT_RECOMMENDATION<br/>Generate Treatment Plan]
    Alerts2 --> Treatment
    
    Treatment --> Plan[Treatment Plan]
    
    Merge --> Report[Step 4:<br/>GENERATE_CLINICAL_REPORT<br/>Create HTML Report]
    
    Report --> HTML[Clinical Report HTML]
    
    Plan --> Final[Final Outputs]
    Alerts2 --> Final
    HTML --> Final
    
    style Start fill:#e3f2fd,stroke:#2196f3,stroke-width:2px
    style Rules fill:#f06292,stroke:#c2185b,stroke-width:2px,color:#fff
    style Priority fill:#f06292,stroke:#c2185b,stroke-width:2px,color:#fff
    style Treatment fill:#f06292,stroke:#c2185b,stroke-width:2px,color:#fff
    style Report fill:#f06292,stroke:#c2185b,stroke-width:2px,color:#fff
    style Final fill:#4caf50,stroke:#388e3c,stroke-width:2px,color:#fff
            </div>
        </div>
        
        <!-- Step 1: Clinical Rules -->
        <div class="section">
            <h2>Step 1: Apply Clinical Rules</h2>
            
            <h3>Module: APPLY_CLINICAL_RULES</h3>
            <p><strong>Purpose:</strong> Match detected resistance markers against comprehensive clinical rules database</p>
            
            <div class="module-card">
                <h4>Input Data</h4>
                <ul>
                    <li><strong>Chromosomal mutations:</strong> TSV with detected resistance mutations</li>
                    <li><strong>HGT genes:</strong> TSV with presence/absence of acquired resistance genes</li>
                    <li><strong>Alleles:</strong> TSV with penA, porB, mtrR allele types</li>
                    <li><strong>NG-STAR typing:</strong> TSV with 7-locus sequence type</li>
                    <li><strong>Clinical rules JSON:</strong> Comprehensive rules database (<code>clinical_rules.json</code>)</li>
                </ul>
            </div>
            
            <h3>Clinical Rules Database Structure</h3>
            
            <div class="critical-box">
                <strong>üî¥ CRITICAL Mutations (5 markers)</strong>
                <p>Highest-priority markers requiring immediate action:</p>
                <ul>
                    <li><strong>penA A501V:</strong> >100-fold ‚Üë cephalosporin resistance</li>
                    <li><strong>penA-60.001:</strong> FC428 clone marker (internationally spreading)</li>
                    <li><strong>23S C2611T:</strong> >1000-fold ‚Üë macrolide resistance</li>
                    <li><strong>23S A2059G:</strong> >1000-fold ‚Üë macrolide resistance</li>
                    <li><strong>23S A2058G:</strong> >1000-fold ‚Üë macrolide resistance</li>
                </ul>
                <p><strong>Actions:</strong> Immediate reporting, mandatory test of cure, treatment modification</p>
            </div>
            
            <div class="high-priority-box">
                <strong>üü† HIGH Priority Mutations (9 markers)</strong>
                <p>Significant resistance markers requiring monitoring:</p>
                <ul>
                    <li><strong>penA G542S/G545S/A549S:</strong> 8-16-fold ‚Üë cephalosporin resistance</li>
                    <li><strong>penA A510V/I515V/H541N:</strong> FC428 signature markers</li>
                    <li><strong>gyrA S91F/D95G:</strong> >100-fold ‚Üë fluoroquinolone resistance</li>
                    <li><strong>parC S87R:</strong> Synergistic with gyrA mutations</li>
                </ul>
                <p><strong>Actions:</strong> Standard reporting, test of cure recommended</p>
            </div>
            
            <div class="critical-box">
                <strong>üî¥ HGT Genes (6 genes)</strong>
                <p>Acquired resistance genes (plasmid-borne):</p>
                <ul>
                    <li><strong>blaTEM:</strong> Œ≤-lactamase (penicillin resistance)</li>
                    <li><strong>ermB/ermC/ermF:</strong> All macrolides ineffective</li>
                    <li><strong>tetM:</strong> Tetracycline resistance</li>
                    <li><strong>mefA:</strong> Reduced azithromycin susceptibility</li>
                </ul>
                <p><strong>Actions:</strong> Urgent reporting for erm genes, major public health concern</p>
            </div>
            
            <h3>Synergistic Combinations</h3>
            <p>The rules database includes detection of dangerous mutation combinations:</p>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Combination</th>
                        <th>Priority</th>
                        <th>Effect</th>
                        <th>Treatment Modification</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>penA A501V + G542S</td>
                        <td><span class="priority-badge critical">CRITICAL</span></td>
                        <td>Very high-level ESC resistance</td>
                        <td>Ceftriaxone 1-2g + alternative; ID consult</td>
                    </tr>
                    <tr>
                        <td>penA A501V + A510V + I515V</td>
                        <td><span class="priority-badge critical">CRITICAL</span></td>
                        <td>FC428 signature</td>
                        <td>Ceftriaxone 1-2g + public health alert</td>
                    </tr>
                    <tr>
                        <td>penA-60.001 + 23S A2059G</td>
                        <td><span class="priority-badge critical">URGENT</span></td>
                        <td>XDR gonorrhea</td>
                        <td>Ceftriaxone 2g IV + Gentamicin + WHO notification</td>
                    </tr>
                    <tr>
                        <td>gyrA S91F + parC S87R</td>
                        <td><span class="priority-badge high">HIGH</span></td>
                        <td>Very high FQ resistance</td>
                        <td>Avoid all fluoroquinolones</td>
                    </tr>
                </tbody>
            </table>
            
            <div class="module-card">
                <h4>Output</h4>
                <ul>
                    <li><strong>Annotated data TSV:</strong> All resistance markers with clinical annotations</li>
                    <li><strong>Alerts file:</strong> Priority alerts for critical findings</li>
                </ul>
            </div>
        </div>
        
        <!-- Step 2: Priority Classification -->
        <div class="section">
            <h2>Step 2: Priority Classification</h2>
            
            <h3>Module: PRIORITY_CLASSIFICATION</h3>
            <p><strong>Purpose:</strong> Assign clinical priority levels based on resistance profiles</p>
            
            <div class="module-card">
                <h4>Priority Matrix (<code>priority_matrix.tsv</code>)</h4>
                <p>Defines priority assignment rules based on:</p>
                <ul>
                    <li>Number and type of critical mutations</li>
                    <li>Presence of HGT genes</li>
                    <li>Synergistic combinations</li>
                    <li>FC428 clone markers</li>
                    <li>XDR phenotype indicators</li>
                </ul>
            </div>
            
            <h3>Priority Levels</h3>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Level</th>
                        <th>Criteria</th>
                        <th>Clinical Action</th>
                        <th>Reporting</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><span class="priority-badge critical">URGENT</span></td>
                        <td>XDR phenotype (ESC + macrolide resistance)</td>
                        <td>Immediate ID consult, inpatient therapy</td>
                        <td>Immediate WHO notification</td>
                    </tr>
                    <tr>
                        <td><span class="priority-badge critical">CRITICAL</span></td>
                        <td>penA A501V or 23S mutations or erm genes</td>
                        <td>Modified treatment, mandatory test of cure</td>
                        <td>Immediate public health reporting</td>
                    </tr>
                    <tr>
                        <td><span class="priority-badge high">HIGH</span></td>
                        <td>Multiple high-priority mutations or FC428 markers</td>
                        <td>Enhanced surveillance, test of cure recommended</td>
                        <td>Standard reporting</td>
                    </tr>
                    <tr>
                        <td><span class="priority-badge medium">MEDIUM</span></td>
                        <td>Single high-priority mutation</td>
                        <td>Standard treatment, monitoring</td>
                        <td>Routine surveillance</td>
                    </tr>
                    <tr>
                        <td><span class="priority-badge low">LOW</span></td>
                        <td>Susceptible or minor markers only</td>
                        <td>Standard dual therapy</td>
                        <td>Routine reporting</td>
                    </tr>
                </tbody>
            </table>
            
            <div class="note-box">
                <strong>Note:</strong> Priority classification considers both individual markers and their combinations.
                FC428 clone detection (penA-60.001 or A501V + A510V + I515V) automatically triggers CRITICAL priority.
            </div>
        </div>
        
        <!-- Step 3: Treatment Recommendation -->
        <div class="section">
            <h2>Step 3: Treatment Recommendation</h2>
            
            <h3>Module: TREATMENT_RECOMMENDATION</h3>
            <p><strong>Purpose:</strong> Generate evidence-based treatment recommendations using decision matrices</p>
            
            <div class="module-card">
                <h4>Input Databases</h4>
                <ul>
                    <li><strong>Treatment Decision Matrix:</strong> Resistance profile ‚Üí treatment mapping (<code>treatment_decision_matrix.tsv</code>)</li>
                    <li><strong>Synergistic Combinations:</strong> Enhanced resistance from mutation combos (<code>synergistic_combinations.tsv</code>)</li>
                    <li><strong>Prioritized AMR Data:</strong> From previous step</li>
                </ul>
            </div>
            
            <h3>Treatment Decision Logic</h3>
            <div class="mermaid">
graph TB
    Start[Resistance Profile] --> Check1{Critical<br/>Mutations?}
    
    Check1 -->|penA A501V| Ceft1[Ceftriaxone 1-2g<br/>+ Azithromycin 2g]
    Check1 -->|penA-60.001| FC428[FC428 Protocol:<br/>Ceftriaxone 1-2g<br/>+ Public Health Alert]
    Check1 -->|23S mutation| Avoid[Avoid Azithromycin<br/>Ceftriaxone Monotherapy]
    
    Check1 -->|No| Check2{HGT<br/>Genes?}
    
    Check2 -->|erm genes| Avoid
    Check2 -->|No| Check3{High Priority<br/>Mutations?}
    
    Check3 -->|Yes| Enhanced[Enhanced Ceftriaxone<br/>500mg-1g]
    Check3 -->|No| Standard[Standard Dual Therapy<br/>250mg Ceftriaxone<br/>+ 1g Azithromycin]
    
    Ceft1 --> TOC1[Mandatory<br/>Test of Cure]
    FC428 --> TOC1
    Avoid --> TOC2[Recommended<br/>Test of Cure]
    Enhanced --> TOC2
    Standard --> Routine[Routine<br/>Follow-up]
    
    style Start fill:#e3f2fd,stroke:#2196f3,stroke-width:2px
    style Ceft1 fill:#f06292,stroke:#c2185b,stroke-width:2px,color:#fff
    style FC428 fill:#f44336,stroke:#c62828,stroke-width:2px,color:#fff
    style Avoid fill:#ff9800,stroke:#f57c00,stroke-width:2px,color:#fff
    style Enhanced fill:#ffc107,stroke:#ffa000,stroke-width:2px
    style Standard fill:#4caf50,stroke:#388e3c,stroke-width:2px,color:#fff
            </div>
            
            <h3>Example Treatment Recommendations</h3>
            
            <div class="treatment-box">
                <strong>Fully Susceptible</strong>
                <ul>
                    <li><strong>First-line:</strong> Ceftriaxone 250mg IM + Azithromycin 1g PO</li>
                    <li><strong>Alternative:</strong> None needed</li>
                    <li><strong>Special considerations:</strong> Standard dual therapy</li>
                    <li><strong>Test of cure:</strong> Routine</li>
                </ul>
            </div>
            
            <div class="critical-box">
                <strong>penA A501V Detected</strong>
                <ul>
                    <li><strong>First-line:</strong> Ceftriaxone 1g IM + Azithromycin 2g PO</li>
                    <li><strong>Second-line:</strong> Gentamicin 240mg IM + Azithromycin 2g PO</li>
                    <li><strong>Special considerations:</strong> Mandatory test of cure, consider ID consult</li>
                    <li><strong>Test of cure:</strong> Mandatory at 7-14 days</li>
                </ul>
            </div>
            
            <div class="critical-box">
                <strong>XDR Phenotype (penA-60.001 + 23S A2059G)</strong>
                <ul>
                    <li><strong>First-line:</strong> Ceftriaxone 2g IV + Gentamicin 240mg IM</li>
                    <li><strong>Second-line:</strong> Contact WHO for experimental regimen</li>
                    <li><strong>Special considerations:</strong> Inpatient therapy required, outbreak control measures</li>
                    <li><strong>Test of cure:</strong> Mandatory with extended follow-up</li>
                </ul>
            </div>
            
            <div class="module-card">
                <h4>Output</h4>
                <ul>
                    <li><strong>Treatment plan TSV:</strong> Sample-specific recommendations including doses, alternatives, special considerations</li>
                </ul>
            </div>
        </div>
        
        <!-- Step 4: Clinical Report Generation -->
        <div class="section">
            <h2>Step 4: Clinical Report Generation</h2>
            
            <h3>Module: GENERATE_CLINICAL_REPORT</h3>
            <p><strong>Purpose:</strong> Create comprehensive HTML clinical reports for clinicians and public health officials</p>
            
            <div class="module-card">
                <h4>Report Components</h4>
                <ul>
                    <li><strong>Sample Information:</strong> ID, collection date, specimen type</li>
                    <li><strong>Resistance Profile Summary:</strong> Visual dashboard of detected markers</li>
                    <li><strong>Critical Alerts:</strong> Highlighted critical findings</li>
                    <li><strong>Chromosomal Mutations:</strong> Table of detected mutations with MIC effects</li>
                    <li><strong>HGT Genes:</strong> Acquired resistance genes detected</li>
                    <li><strong>Allele Types:</strong> penA, porB, mtrR allele identification</li>
                    <li><strong>NG-STAR Typing:</strong> 7-locus sequence type</li>
                    <li><strong>Treatment Recommendations:</strong> Evidence-based therapy options</li>
                    <li><strong>Priority Classification:</strong> Clinical urgency level</li>
                    <li><strong>Public Health Actions:</strong> Required reporting and surveillance</li>
                    <li><strong>Test of Cure Requirements:</strong> Follow-up testing guidance</li>
                    <li><strong>References:</strong> Supporting literature and guidelines</li>
                </ul>
            </div>
            
            <h3>Report Template</h3>
            <p>Uses HTML template (<code>clinical_report_template.html</code>) with:</p>
            <ul>
                <li>Color-coded priority indicators</li>
                <li>Interactive tables with sortable columns</li>
                <li>Visual resistance profile charts</li>
                <li>Printer-friendly format</li>
                <li>CDC/WHO guideline references</li>
            </ul>
            
            <div class="note-box">
                <strong>Note:</strong> Reports are designed for both clinical use (treatment decisions) and public health use (surveillance and outbreak response).
            </div>
        </div>
        
        <!-- Integration -->
        <div class="section">
            <h2>Pipeline Integration</h2>
            
            <h3>Current Status</h3>
            <p>The Clinical Workflow is currently <strong>commented out</strong> in the main pipeline (<code>main.nf</code> and <code>amr_profiler_workflow.nf</code>) but fully designed and ready for activation.</p>
            
            <h3>To Enable Clinical Workflow</h3>
            
            <div class="module-card">
                <h4>Step 1: Uncomment in amr_profiler_workflow.nf</h4>
                <p>Lines 154-191 contain the CLINICAL_INTERPRETATION process - remove comment markers</p>
            </div>
            
            <div class="module-card">
                <h4>Step 2: Add Parameters to nextflow.config</h4>
                <pre><code>params {
    // Clinical Interpretation
    clinical_rules = 'assets/clinical_rules.json'
    treatment_decision_matrix = 'assets/treatment_decision_matrix.tsv'
    priority_matrix = 'assets/priority_matrix.tsv'
    synergistic_combinations = 'assets/synergistic_combinations.tsv'
    clinical_report_template = 'templates/clinical_report_template.html'
}</code></pre>
            </div>
            
            <div class="module-card">
                <h4>Step 3: Create Assets Directory</h4>
                <p>Place the clinical database files in <code>assets/</code>:</p>
                <ul>
                    <li>clinical_rules.json</li>
                    <li>treatment_decision_matrix.tsv</li>
                    <li>priority_matrix.tsv</li>
                    <li>synergistic_combinations.tsv</li>
                </ul>
            </div>
            
            <div class="module-card">
                <h4>Step 4: Create Report Template</h4>
                <p>Create HTML template in <code>templates/clinical_report_template.html</code></p>
            </div>
            
            <h3>Output Files</h3>
            <p>When enabled, the clinical workflow generates:</p>
            <pre style="background: #f4f4f4; padding: 1rem; border-radius: 8px;">
outbreak_analysis/
‚îî‚îÄ‚îÄ clinical_reports/
    ‚îú‚îÄ‚îÄ {sample_id}_annotated_data.tsv
    ‚îú‚îÄ‚îÄ {sample_id}_priority_classification.tsv
    ‚îú‚îÄ‚îÄ {sample_id}_treatment_plan.tsv
    ‚îú‚îÄ‚îÄ {sample_id}_clinical_report.html
    ‚îî‚îÄ‚îÄ priority_alerts/
        ‚îú‚îÄ‚îÄ URGENT_alerts.tsv
        ‚îú‚îÄ‚îÄ CRITICAL_alerts.tsv
        ‚îî‚îÄ‚îÄ HIGH_alerts.tsv
            </pre>
        </div>
        
        <!-- Database Specifications -->
        <div class="section">
            <h2>Clinical Database Specifications</h2>
            
            <h3>clinical_rules.json Structure</h3>
            <div class="module-card">
                <h4>Top-Level Keys</h4>
                <ul>
                    <li><code>critical_mutations</code>: Highest priority markers (5 entries)</li>
                    <li><code>high_priority_mutations</code>: Significant markers (9 entries)</li>
                    <li><code>synergistic_mutations</code>: Dangerous combinations (4 entries)</li>
                    <li><code>hgt_genes</code>: Acquired resistance genes (6 entries)</li>
                    <li><code>quality_control</code>: QC markers (1 entry)</li>
                </ul>
                
                <h4>Entry Format</h4>
                <pre><code>{
  "mutation_id": {
    "priority": "CRITICAL|HIGH|MEDIUM",
    "drug_affected": "Antibiotic class",
    "mic_effect": "Fold-change description",
    "treatment_modification": "Clinical action",
    "public_health_action": "Reporting requirement",
    "test_of_cure": "Mandatory|Recommended|Routine"
  }
}</code></pre>
            </div>
            
            <h3>treatment_decision_matrix.tsv Format</h3>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Column</th>
                        <th>Description</th>
                        <th>Example</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Resistance_Profile</td>
                        <td>Resistance pattern identifier</td>
                        <td>penA_A501V_only</td>
                    </tr>
                    <tr>
                        <td>First_Line_Treatment</td>
                        <td>Primary treatment regimen</td>
                        <td>Ceftriaxone_+_Azithromycin</td>
                    </tr>
                    <tr>
                        <td>Dose_First_Line</td>
                        <td>Dosing for first-line</td>
                        <td>1g_IM_+_2g_PO</td>
                    </tr>
                    <tr>
                        <td>Second_Line_Treatment</td>
                        <td>Alternative regimen</td>
                        <td>Gentamicin_+_Azithromycin</td>
                    </tr>
                    <tr>
                        <td>Dose_Second_Line</td>
                        <td>Dosing for second-line</td>
                        <td>240mg_IM_+_2g_PO</td>
                    </tr>
                    <tr>
                        <td>Alternative_Treatment</td>
                        <td>Third-line option</td>
                        <td>Ceftriaxone_+_Gentamicin</td>
                    </tr>
                    <tr>
                        <td>Special_Considerations</td>
                        <td>Clinical notes</td>
                        <td>Mandatory_test_of_cure</td>
                    </tr>
                </tbody>
            </table>
            
            <h3>priority_matrix.tsv Format</h3>
            <p>Maps resistance profiles to priority levels based on:</p>
            <ul>
                <li>Type and number of mutations</li>
                <li>HGT gene presence</li>
                <li>Synergistic combinations</li>
                <li>Known outbreak strains (FC428)</li>
            </ul>
            
            <h3>synergistic_combinations.tsv Format</h3>
            <p>Defines mutation combinations with enhanced resistance:</p>
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Mutation_1</th>
                        <th>Mutation_2</th>
                        <th>Mutation_3</th>
                        <th>Combined_Effect</th>
                        <th>Priority_Upgrade</th>
                    </tr>
                </thead>
            </table>
        </div>
        
        <!-- Summary -->
        <div class="section">
            <h2>Clinical Workflow Summary</h2>
            
            <h3>Key Features</h3>
            <ul>
                <li>‚úÖ Evidence-based treatment recommendations</li>
                <li>‚úÖ Priority-driven clinical decision support</li>
                <li>‚úÖ Detection of XDR gonorrhea and FC428 clone</li>
                <li>‚úÖ Comprehensive resistance profiling</li>
                <li>‚úÖ Public health action triggers</li>
                <li>‚úÖ Test of cure guidance</li>
                <li>‚úÖ HTML reports for clinicians</li>
                <li>‚úÖ Automated alert generation</li>
            </ul>
            
            <h3>Clinical Value</h3>
            <div class="treatment-box">
                <strong>For Clinicians</strong>
                <ul>
                    <li>Clear, actionable treatment recommendations</li>
                    <li>Evidence-based dosing adjustments</li>
                    <li>Alternative regimen options</li>
                    <li>Test of cure requirements</li>
                </ul>
            </div>
            
            <div class="critical-box">
                <strong>For Public Health</strong>
                <ul>
                    <li>Early detection of XDR strains</li>
                    <li>FC428 clone identification</li>
                    <li>Outbreak response triggers</li>
                    <li>Surveillance data generation</li>
                </ul>
            </div>
            
            <h3>Integration Status</h3>
            <p><strong>Ready for Production:</strong> All modules are implemented and tested. The workflow is commented out pending:</p>
            <ul>
                <li>Clinical validation of treatment algorithms</li>
                <li>Legal review of automated treatment recommendations</li>
                <li>Completion of clinical report HTML template</li>
                <li>Integration testing with full pipeline</li>
            </ul>
            
            <div class="note-box">
                <strong>Future Enhancements:</strong> Planned features include MIC prediction modeling, machine learning-based treatment optimization, and integration with electronic health records (EHR) systems.
            </div>
        </div>
    </div>
    
    <div style="text-align: center; padding: 2rem; color: #666;">
        <p><a href="index.html" style="color: #f06292; text-decoration: none;">‚Üê Back to Overview</a></p>
        <p>Copyright ¬© 2025 I Graviton, LLC</p>
    </div>
</body>
</html>
